Skip to content
Back to meeting Original
Kohji Takemura, MD· @KohjiToncol · X·· 3 days agoScore45

JNJ-6143

Body

JNJ-6143: A first-in-class RIPTAC with a novel mechanism of action targeting AR and BRD4.

Promising phase 1 efficacy and safety in heavily pretreated mCRPC.

Potential activity even in patients with high-risk molecular features. Looking forward to further development!

#ESMO26

15 views · 0 likes · 0 reposts · 0 replies

Source: Kohji Takemura, MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.